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any medium, provided the original work is propertoxicity issues to date. Nanoformulation of p38 MAPK inhibitors may overcome these challenges,
by enabling controlled release and targeted delivery. Thus, the aimof this studywas to develop a
nanoformulation of the p38 MAPK inhibitor GSK 678361A and subsequently validate its
anti-inﬂammatory efﬁcacy in vitro, versus the drug in its free format. Poly(lactic-co-glycolic
acid) nanoparticles encapsulating GSK 678361A were prepared via a salting-out method and
characterised by photon correlation spectroscopy, scanning electron microscopy and
high-performance liquid chromatography. The anti-inﬂammatory effect of both free and
nanoformulatedGSK 678361Awas evaluated in cultures of lipopolysaccharide-stimulatedmacro-
phages, with subsequent enzyme-linked immunosorbent assay analysis of TNF-α and IL-6 provid-
ing readouts of efﬁcacy. A controlled release nanoformulation of GSK 678361A was successfully
developed, with physicochemical characterisation revealing an average particle diameter of
115.5 ± 3.5 nmand polydispersity index of 0.13 ± 0.03, indicative of a homogeneous size distribu-
tion. GSK 678361A loading was quantiﬁed at 10.1 ± 0.4μg permg of poly(lactic-co-glycolic acid),
equating to an entrapment efﬁciency of approximately 50%. When tested in cultures of
lipopolysaccharide-stimulated macrophages, GSK 678361A nanoparticles inhibited the produc-
tion of pro-inﬂammatory cytokines to an extent that was largely comparable with the free drug,
although superior efﬁcacy of the nanoformulationwas observed at selected doses. These studies
indicate that GSK 678361A may be successfully nanoformulated without loss of drug activity,
warranting further evaluation in models of inﬂammation in vivo. © 2016 The Authors. Journal
of Interdisciplinary Nanomedicine published by John Wiley & Sons Ltd and the British Society
for Nanomedicineanomedicine published by John Wiley & Sons Ltd and the British Society for Nanomedicine
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p38 Inhibitor Nanoparticles B. K. Bains et al.Introduction
p38 Mitogen-activated protein kinase (MAPK) is a serine-
threonine kinase that forms part of the mammalian MAPK
family, alongside other members such as extracellular
signal-regulated kinase and c-Jun NH2-terminal kinase
(Kim and Choi, 2010). It exists in several isoforms, namely,
p38-α, -β, -γ and -δ, which are activated in response to en-
vironmental stresses or inﬂammatory cytokines (Cuenda
and Rousseau, 2007). Upon activation, p38 MAPK medi-
ates a diverse array of functions, including the regulation
of cell differentiation, proliferation and apoptosis
(Coulthard et al., 2009). Moreover, it also performs a fun-
damental role in initiating pro-inﬂammatory cytokine
production and has been shown to modulate cytokine
expression at both transcriptional and translational levels
(Cargnello and Roux, 2011). As such, p38 MAPK inhibitors
are currently being pursued as potential treatment candi-
dates in conditions underpinned by inﬂammation.
The therapeutic potential of p38 MAPK inhibitors has
been examined in several models of inﬂammatory dis-
ease, including rheumatoid arthritis, atherosclerosis,
Alzheimer’s disease, psoriasis, asthma and chronic ob-
structive pulmonary disease (Underwood et al., 2000;
Nishikawa et al., 2003; Munoz et al., 2007; Medicherla
et al., 2008; Medicherla et al., 2010; Seeger et al.,
2010). However, progression of these compounds to clin-
ical approval has been limited because of factors such as
poor efﬁcacy or adverse side-effects (Cohen et al.,
2009; Damjanov et al., 2009; Genovese et al., 2011).
To overcome such limitations, p38 MAPK inhibitors
may be integrated within targeted drug delivery sys-
tems such as nanoparticles. This strategy affords nu-
merous advantages, including enhanced bioavailability
and a reduction in toxicity arising from off-target
effects. Moreover, nanoformulation enables sustained
release of the payload with a subsequent reduction in
dosing schedules and enhanced patient compliance
(Gelperina et al., 2005; Parveen et al., 2012).
In this study,we aimed to develop a polymeric nanopar-
ticle platform encapsulating the p38 MAPK inhibitor GSK
678361A (Triantaphyllopoulos et al., 2010), with
controlled release properties. We examined the ability
of this nanoparticle to inhibit pro-inﬂammatory cytokine
production by murine macrophages in both a time-
dependent and dose-dependent manner.
Materials and Methods
Dimethyl sulphoxide (DMSO), acetone, dichlorometh-
ane, poly (vinyl alcohol) (PVA), N-cyclohexyl-3-
aminopropanesulfonic acid (CAPS), magnesium chloride2016 | Volume 1 | Issue 3 |
Page 86hexahydrate, low endotoxin foetal bovine serum and
low endotoxin phosphate buffered saline (PBS) were
purchased from Sigma Aldrich (UK). Poly(lactic-co-
glycolic acid) (PLGA RG502H), with a molecular weight
range of 7–17kDa, was purchased from Evonik Industries
(Germany). Slide-A-Lyzer® mini dialysis units 7K MWCO
were purchased from Thermo Fisher Scientiﬁc Inc (UK).
C57BL/6 mice were purchased from Harlan Laboratories
(UK). Dulbecco’s modiﬁed Eagle’s medium, penicillin
and streptomycin were purchased from Gibco, Life Tech-
nologies (UK). Escherichia coli R515 lipopolysaccharide
(LPS) was purchased from Enzo life sciences (UK). Murine
TNF-α and IL-6 DuoSet enzyme-linked immunosorbent as-
says (ELISAs) were purchased from R&D systems (UK). GSK
678361A was a generous gift from GlaxoSmithKline (UK).Nanoparticle preparation
GSK 678361A-loaded nanoparticles (GSK 678361A NP)
were prepared using an emulsion evaporation salting-
out method adapted from McCarron et al. (2006). PLGA
RG502H (20mg) was dissolved in 500μL acetone and
300μL dichloromethane. GSK 678361A dissolved in
DMSO (10mg/mL) was pipetted (40μL) into the PLGA
mix. The PLGA-drug organic phase was injected
dropwise into the aqueous phase (3mL) comprising
2.5% (w/v) PVA and 45% (w/v) MgCl2 in CAPS buffer
(20mM, pH9.0). An emulsion was formed using
pulsatory sonication (50 amplitude) on ice for 90 sec.
Additional aqueous phase (5mL) (2.5% w/v PVA in CAPS
buffer 20mM, pH9.0) was gradually added to the emul-
sion, under continual stirring, to initiate selective
acetone diffusion. Stirring was continued overnight to
ensure evaporation of the organic phase. Nanoparticles
were puriﬁed in CAPS buffer (pH 9) using three wash-
centrifugation (60,000 rcf, 20min, 4°C) cycles.GSK 678361A entrapment efﬁciency
GSK 678361A entrapment efﬁciency was determined
using high-performance liquid chromatography (HPLC).
The puriﬁed NP pellet was dissolved in DMSO and
acetonitrile (ACN) (1:3) and measured at 254 nm wave-
length using a validated HPLC method. HPLC comprised
a Varian Prostar Spectra system with a C-18 HPLC
column (50 ×4.6mm diameter, 5μM pore size)
(Phenomenex, UK). The mobile phase (ﬂow rate of
1mL/min) consisted of solvent A (H2O) and solvent B
(ACN+0.05% TFA) with elution over a linear gradient of
solvent B 10–100% over 5min. Results were compared
to a standard calibration curve of GSK 678361A solution
p38 Inhibitor NanoparticlesB. K. Bains et al.in DMSO : ACN (1:3). Entrapment efﬁciency was calcu-
lated as follows:
Entrapment efficiency %ð Þ ¼ Mass of drug determined μgð Þ
Mass of drug added μgð Þ x 100
Nanoparticle characterisation
Nanoparticle size and polydispersity index (PDI) were
measured in PBS using photon correlation spectroscopy
(Zetasizer Nano ZS, Malvern instruments, UK). Measure-
ments were carried out at room temperature. Each
sizing determination was carried out in triplicate, and
an average particle size was expressed as the mean
diameter (Zave). Routine size measurements and sur-
face morphology were conﬁrmed by scanning electron
microscopy (SEM). Nanoparticles were mounted onto
copper tape covering an aluminium stub, sputter
coated with gold and visualised by SEM (Jeol 6500 ﬁeld
emission gun, Japan).
Evaluation of GSK 678361A release from poly
(lactic-co-glycolic acid) nanoparticles
Release proﬁles of GSK 678361A were determined using
a dialysis-based method. A mass of nanoparticles
equivalent to approximately 150μg GSK 678361A was
dispersed in 2mL growth media (Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% low endotoxin
FCS, 1% penicillin and streptomycin). The nanoparticle
solution was injected into a pre-wetted Slide-A-Lyzer®
dialysis cassette with a 7K molecular weight cut-off
(Pierce Biotechnology, USA) using a 21 gauge bevelled
needle and immersed into a reservoir of 28mL
pre-warmed growth media. The release study was
performed at 37°C under conditions of continuous
stirring. Samples (200μL) were removed from the
reservoir at deﬁned time points. GSK 678361A concen-
tration was measured using a validated HPLC protocol
as described previously and compared with a calibra-
tion curve for standard GSK 678361A solutions prepared
under similar conditions.Cell preparation and culture
Bone marrow-derived macrophages (BMDM) were iso-
lated from the femur and tibia of C57BL/6 female
mice. The femur and tibia were removed from the fe-
male donors, and marrow was ﬂushed out using a 23
gauge needle and syringe containing growth media.
The bone marrow was pelleted at 650 rcf for 8min at
4°C, and lysis buffer was used to lyse red blood cells.
Cells were differentiated into macrophages by cultur-
ing them in the presence of growth media containing20% L929 supernatant as a source of macrophage-colony
stimulating factor. Culture medium was changed on day
three to remove non-adherent cells. After seven days,
cells were counted and seeded into 96 well plates at a
density of 5 × 104 cells/well and allowed to rest over-
night in non-L929 supplemented growth media.
Effect of GSK 678361A on
lipopolysaccharide-stimulated cytokine
production
The efﬁcacy of GSK 678361A in either the free or nano-
encapsulated form was assessed using murine BMDM.
Cells were stimulated with 100 ng/mL E. coli R515 LPS
and left to incubate for 1 h prior to further treatment
with 2μM free GSK 678361A or 2μM GSK 678361A NP
reconstituted in low endotoxin PBS. Cells were
incubated for a further 5 h, after which supernatants
were collected and analysed by ELISA.
GSK 678361A dose response
Bone marrow-derived macrophages (BMDM) were
pre-treated with LPS as described previously and then
further treated with increasing concentrations (ranging
from 104 to 10μM/225μL) of GSK 678361A suspended
in DMSO or GSK 678361A NP reconstituted in low
endotoxin PBS. Cells were incubated for a further
5 h, after which supernatants were collected and
analysed by ELISA. Cytokine concentrations were com-
pared to those of cells treated with the respective
positive controls, DMSO or Blank NP, as a means of
calculating therapeutic percentage inhibition of
cytokine levels.
Determination of GSK 678361A effect over time
Bone marrow-derived macrophages (BMDM) were
treated with 2μM free GSK 678361A or 2μM GSK
678361A NP reconstituted in low endotoxin PBS at 1 h
post-LPS treatment as described previously. Superna-
tants were collected at pre-determined time points
and analysed by ELISA.
Statistical analysis
Statistical signiﬁcance between data groups was
determined using Student’s t-test or one way analysis
of variance (ANOVA) with Tukey post-hoc test. Where
statistical signiﬁcance was achieved, it was repre-
sented by asterisks in the appropriate ﬁgures and
deﬁned as: ***P< 0.001, **P< 0.01, *P<0.05. All analy-
ses were performed using GraphPad Prism software
(GraphPad software, USA).2016 | Volume 1 | Issue 3 |
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Figure 2. GSK 678361A release proﬁle from PLGA nanoparticles:
GSK 678361A NP were resuspended in growth media, injected into
a dialysis cassette and incubated at 37°C. Samples were collected
at predeﬁned time points, and GSK 678361A concentration was
quantiﬁed using a validated high-performance liquid chromatogra-
phy method. Data expressed as mean ± SEM.
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Nanoparticle characterisation
Nanoparticle size analysis was performed via photon
correlation spectroscopy, revealing an average diame-
ter of 115.5 ± 3.5 nm for GSK 678361A NP (Fig. 1A).
The size distribution of the GSK 678361A NP formulation
was relatively monodisperse, as indicated by a low PDI
value of 0.13 ± 0.03 (Fig. 1A). Using validated HPLC
methods, the entrapment efﬁciency of GSK 678361A
within PLGA nanoparticles was measured at 50.6
± 2.2%, equating to 10.1 ± 0.4μg drug per mg of polymer
(Fig. 1A). SEM analysis also conﬁrmed the presence of a
homogeneous population of nanoparticles, with similar
diameters to those obtained via photon correlation
spectroscopy (Fig. 1B). Finally, the drug release from
these particles was examined at 37°C under continuous
stirring conditions, demonstrating a typical biphasic
release kinetic, with an initial burst release of 75.7
± 8.4% of the drug during the ﬁrst 24 h, followed by a
slower sustained release lasting until the 144 h time
point (Fig. 2).Effect of GSK 678361A on
lipopolysaccharide-stimulated cytokine
production
Following optimisation of the GSK 678361A NP formula-
tion, functional assays were performed to assess the
anti-inﬂammatory efﬁcacy of both GSK 678361A NP
and free GSK 678361A in LPS-stimulated BMDM cultures.
As anticipated, LPS stimulation signiﬁcantly increased
TNF-α and IL-6 levels to 427.1 ± 33.6 and 397.7Figure 1. Characterisation of GSK 678361A NP: (A) Size, polydis-
persity index (PDI) and drug entrapment of GSK 678361A NP. Data
expressed as mean ± SEM. (B) Scanning electron micrograph of GSK
678361A NP. Scale bar = 1 μm.
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treatment with 2μM GSK 678361A was found to signiﬁ-
cantly reduce cytokine levels to 113.0 ± 20.4 pg/mL
(TNF-α) and 235.9 ± 39.6 pg/mL (IL-6) when used in its
free form, and to 132.8 ± 8.4 pg/mL (TNF-α) and 216.2
± 4.3 pg/mL (IL-6) upon nano-encapsulation. No signiﬁ-
cant difference in cytokine levels was observed be-
tween free and nano-encapsulated GSK 678361A,
indicating that both treatments were comparable in
efﬁcacy and that drug activity was preserved upon
loading into nanoparticles.
GSK 678361A dose response
Having conﬁrmed anti-inﬂammatory efﬁcacy of free and
nano-encapsulated GSK 678361A in BMDM cultures, we
next examined the dose-dependency of these effects.
Both TNF-α and IL-6 levels were inhibited by GSK
678361A NP in a dose-dependent manner (Fig. 4A and
B). Maximal inhibition was observed at a concentration
of 10μM, where TNF-α and IL-6 levels were signiﬁcantly
reduced by the GSK 678361A NP (70.9 ± 3.1% and 61.4
± 1.4%, respectively), when compared with free GSK
678361A (50.2 ± 2.0% and 25.1 ± 6.0%, respectively).
Determination of GSK 678361A effect over time
The inhibitory activity of GSK 678361A in both its free
and nano-encapsulated form was next evaluated as a
function of time in LPS-stimulated BMDM. At all time
points, both free and nano-encapsulated GSK 678361A
signiﬁcantly reduced TNF-α levels when compared with
the LPS control (Fig. 5A). The inhibitory effect of GSK
678361A NP on TNF-α production was comparable to
Figure 3. Inhibition of inﬂammatory cytokine production by GSK 678361A NP: Murine bone marrow-derived macrophages were pre-treated
with 100 ng/mL lipopolysaccharide (LPS) for 1 h prior to stimulation with 2 μM free GSK 678361A or the equivalent amount of GSK 678361A
NP. Culture supernatants were collected after 6 h and assayed for both (A) TNF-α and (B) IL-6 by enzyme-linked immunosorbent assay. Sta-
tistical signiﬁcance was assessed by one way ANOVA with Tukey post-hoc test (*P< 0.05, **P< 0.01). Data expressed as mean + SEM.
Figure 4. Dose-dependent inhibition of inﬂammatory cytokine production by GSK 678361A NP: Murine bone marrow-derived macrophages
were pre-treated with 100 ng/mL lipopolysaccharide (LPS) for 1 h prior to stimulation with various concentrations of free GSK 678361A or
the equivalent amount of GSK 678361A NP. Culture supernatants were collected after 6 h and assayed for both (A) TNF-α and (B) IL-6 by
enzyme-linked immunosorbent assay. Statistical signiﬁcance was assessed by Student’s t-test (**P< 0.01). Data expressed as mean + SEM.
p38 Inhibitor NanoparticlesB. K. Bains et al.that of the free drug for up to and including the 6 h time
point. Similar ﬁndings were also noted for IL-6 at 4 and
6h, although the anti-inﬂammatory effect of both free
and nano-encapsulated GSK 678361A had diminished by
8 h (Fig. 5B).
Discussion
In this current work, we have examined the ability to
encapsulate the p38 MAPK inhibitor GSK 678361A, a
biphenylamide originally characterised to produce
anti-inﬂammatory effects in a murine collagen-induced
arthritis model (Aston et al., 2009; Triantaphyllopoulos
et al., 2010). We have demonstrated in this current
work that the inhibitor can be successfully formulated
into a consistent PLGA nanoparticle formulation,
producing anti-inﬂammatory effects towards LPS-
stimulated macrophages.
The p38 MAPKs play central roles in the progression
of signaling pathways that promote a number ofpathological conditions such as rheumatoid arthritis
and asthma (Schett et al., 2008; Coulthard et al.,
2009; Chung, 2011). GSK 678361A was originally devel-
oped as an inhibitor of p38-α, although it and the struc-
turally related clinical lead compound, GW856553X
(Losmapimod), were both found to selectively inhibit
p38-β (Aston et al., 2009), blocking pro-inﬂammatory
cytokine release. Consistent with this earlier work,
here, we found that GSK 678361A was able to block
release of TNF-α and IL-6 from murine BMDM in both
its free and nano-encapsulated form.
Nanoparticle encapsulation represents an area of
formulation science aimed at improving the bioavail-
ability and/or delivery of drug cargos to the disease
site. Various materials can be employed for the
manufacture of such nanoformulations including lipids
for the production of liposomes, which remains the
most widely used nanomedicine approach applied
clinically (Chang and Yeh, 2012). However, other2016 | Volume 1 | Issue 3 |
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Figure 5. Time-dependent inhibition of inﬂammatory cytokine production by GSK 678361A NP: (A) Murine bone marrow-derived macro-
phages were pre-treated with 100 ng/mL lipopolysaccharide (LPS) for 1 h prior to stimulation with 2 μM free GSK 678361A or the equiva-
lent amount of GSK 678361A NP. Culture supernatants were collected after (i) 4, (ii) 6 and (iii) 8 h and assayed for TNF-α by ELISA. (B)
Murine bone marrow-derived macrophages were treated as in (A), and culture supernatants were assayed for IL-6 by enzyme-linked im-
munosorbent assay. Statistical signiﬁcance was assessed by one way ANOVA with Tukey post-hoc test (**P< 0.01, ***P< 0.001). Data
expressed as mean + SEM.
p38 Inhibitor Nanoparticles B. K. Bains et al.nanoformulation approaches can employ biodegradable
and biocompatible polymer systems, which degrade
more slowly than liposomes, providing a sustained or
controlled release window (Kumari et al., 2010; Cheng
et al., 2015). These include polymer systems such as
naturally derived alginate or chitosan nanoparticles,
or synthetic PLGA nanoparticles (Dhar et al., 2008;
Deacon et al., 2015; Fredman et al., 2015). We have
previously worked extensively with PLGA-based nano-
systems, demonstrating the ability to enhance the
targeting of nanoparticles through attachment of anti-
bodies and other ligands on their surface, generating2016 | Volume 1 | Issue 3 |
Page 90therapeutically useful effects (Schmid et al., 2014;
Spence et al., 2015).
We have also previously examined polymeric nano-
particle systems to provide sustained release of active
pharmaceutical ingredients (APIs), demonstrating
enhanced effectiveness of aminoglycoside antibiotics
(Abdelghany et al., 2012; Deacon et al., 2015). In this
current work, we found that nanoformulation of GSK
678361A provided a typical biphasic controlled release
under in vitro conditions, releasing 75% of the drug by
48 h, cumulating in 100% by 4–5days. Using a range of
concentrations, we comparatively examined the ability
p38 Inhibitor NanoparticlesB. K. Bains et al.of both free and nano-encapsulated drugs to inhibit
TNF-α and IL-6 production, showing superior efﬁcacy
of nanoformulated GSK 678361A at 10μM in particular.
These ﬁndings indicated that nanoformulation did not
abrogate the bioavailability of the drug to the cells.
Finally, we examined the persistence of the anti-
inﬂammatory action of GSK 678361A, revealing that
both free and nano-encapsulated drug inhibited the
production of inﬂammatory cytokines similarly up to
6 h in vitro. Although TNF-α inhibition was also main-
tained at 8 h, a loss of efﬁcacy of both free and nano-
encapsulated drug was observed for IL-6 at this time
point. These ﬁndings highlight potential differences in
the manner by which p38 MAPK controls individual
cytokine production and warrants further investigation.
Beneﬁcial effects of the nano-encapsulation of GSK
678361A were only observed at higher concentrations,
although this is not surprising as usefulness of the con-
trolled release effect of the formulation can be difﬁcult
to determine in simplistic closed incubation conditions
and is in keeping with what we and others have ob-
served previously (Abdelghany et al., 2012; Kolate
et al., 2015). However, it is possible that the nanoparti-
cles may elicit further enhanced therapeutic effects
using in vivo study models, where the pharmacokinetics
of the API can be altered signiﬁcantly by nano-
encapsulation. Furthermore, it is well established that
PLGA nanoparticles are relatively hydrophobic and sus-
ceptible to opsonisation by macrophages in circulation;
given the key role that these cells play in mediating in-
appropriate inﬂammation, nanoformulations of GSK
678361A may enhance delivery of the drug to this
target cell to provide enhanced effects.
In summary, here, we have developed and charac-
terised a PLGA nanoparticle formulation encapsulating
the anti-inﬂammatory drug GSK 678361A. We have
shown that the activity of this API when nano-
formulated is equivalent to the free drug and warrants
its further evaluation in models underpinned by acute
and chronic inﬂammation.Acknowledgments
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